other material
confidence high
sentiment negative
materiality 0.75
Caladrius receives Nasdaq extension to Feb 13, 2023 to regain $1 bid price compliance
LISATA THERAPEUTICS, INC.
- Company failed to meet $1 minimum bid price by Aug 17, 2022 initial compliance deadline.
- Nasdaq granted extension to Feb 13, 2023; requires closing bid of $1+ for 10 consecutive days.
- If compliance not demonstrated by Feb 13, 2023, delisting notice will be issued.
- Company may appeal delisting determination, but success cannot be assured.